Diagnostic Imaging and Therapeutic Aspect of PSMA in Prostate Cancer by Michael Hofman

Michael Hofman discusses with Alicia Morgans both the diagnostic and therapeutic aspect of prostate specific membrane antigen (PSMA) in prostate cancer. The sensitivity and specificity of the PSMA PET may offer relevant clinical advantages in the diagnosis of prostate cancer while the physical properties of Lutetium 177 may provide advantages therapeutically. 

Biographies:

Michael Hofman, MBBS (Hons), FRACP, FAANMS, Professor, Molecular Imaging, The University of Melbourne, Nuclear Medicine Physician in the Centre for Cancer Imaging at the Peter MacCallum Cancer Centre in Melbourne, Australia.  He has a broad interest in positron emission tomography (PET), molecular imaging applications in oncology and radionuclide therapy.

Professor Hofman has a vision of improving patient outcomes by using molecular imaging to non-invasively characterize disease thereby enabling improved selection of the most appropriate therapy for an individual patient and better assessment of therapeutic response. He has a particular interest in novel PET radiotracers, including F-18 and Ga-68, and theranostic applications including neuroendocrine and prostate cancers. Currently, he is the principal investigator of a randomized multi-center trial of PSMA PET/CT in PET/CT, a prospective trial of Lu-177 PSMA therapy and a prospective trial investigating the role of PET V/Q scanning in patients with lung cancer.
 
Professor Hofman previously completed a clinical and research fellowship at Guys and St Thomas in London. He is a fellow of the International Cancer Imaging Society (ICIS) and serves on the editorial board of Cancer Imaging, Leukaemia Lymphoma and the Journal of Medical Imaging and Radiation Oncology (JMIRO). He is an inaugural scientific member of the Australasian Radiopharmaceutical Trials Network (ARTnet).

Alicia Morgans, MD, MPH